SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-23-061115
Filing Date
2023-11-08
Accepted
2023-11-08 16:11:05
Documents
9
Period of Report
2023-11-08

Document Format Files

Seq Description Document Type Size
1 6-K 6-k_proxy_fy2023.htm 6-K 33153
2 EX-99.1 vrax-ex99_1.htm EX-99.1 239182
3 EX-99.2 vrax-ex99_2.htm EX-99.2 2440
4 EX-99.3 vrax-ex99_3.htm EX-99.3 323847
5 EX-99.4 vrax-ex99_4.htm EX-99.4 703813
6 GRAPHIC img90995475_0.jpg GRAPHIC 255769
7 GRAPHIC img90995475_1.jpg GRAPHIC 340403
8 GRAPHIC img90995475_2.jpg GRAPHIC 464007
9 GRAPHIC img92842517_0.jpg GRAPHIC 13253
  Complete submission text file 0000950170-23-061115.txt   2782313
Mailing Address 30 BROADWICK STREET LONDON X0 W1F 8LX
Business Address 30 BROADWICK STREET LONDON X0 W1F 8LX 44 020 7788 7414
Virax Biolabs Group Ltd (Filer) CIK: 0001885827 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-41440 | Film No.: 231387946
SIC: 2835 In Vitro & In Vivo Diagnostic Substances